FutuurVerfügbarkeit prüfenVerifizierte AuflösungsdatenAktuelle implizite Wahrscheinlichkeit
Nein 81%
Nein 81%Marktqualitat
33 / 100
Niedrige Qualität24h-Volumen
—
Liquidität
1044 €
Niedrige LiquiditätTrader
4
Kommentare
0
Marktdaten
Aktualisiert vor 1 Minute
Trends
Verwandte Märkte
Verwandte Fragen als Kontext, kein Vergleich gleichwertiger Kontrakte.
When will the FDA approve Compass Pathways' COMP360 Psilocybin?
KalshiThe FDA will approve a drug for the treatment of senescence (aging) before the end of the decade (before 2030)
Manifold MarketsWill the FDA approve Viagra as a treatment for Alzheimer's before 2030?
Manifold MarketsWill the FDA approve a disease-modifying treatment for Parkinson's disease before 2029?
Manifold MarketsWill the FDA approve any psychedelic substance for medical use this year?
KalshiWill the FDA approve MDMA for PTSD?
KalshiRegeln
This market predicts whether the U.S. Food and Drug Administration (FDA) will grant approval for a psilocybin-containing therapy for any clinical indication during calendar year 2026.
- If, in this period, the FDA grants marketing approval (including standard, accelerated, or priority review approval) to a drug product whose active pharmaceutical ingredient is psilocybin for any human clinical indication, this market will resolve to "Yes".
- Otherwise, it will resolve to "No".
- The Primary Designated Source is the FDA Drug Approvals database and the FDA Orange Book.
- Breakthrough Therapy designation, Fast Track designation, end-of-Phase consultations, advisory committee recommendations, and Investigational New Drug authorizations do NOT count as approval.
- Approval requires a final FDA marketing authorization (NDA or BLA approval letter).
